Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
Vir Biotechnology has reported that its Phase III ECLIPSE 1 trial assessing an investigational combination for CHD met its primary endpoint.
The post Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials appeared first on Clinical Trials Arena .